Speakers

Leandro Gandos Brito is incoming Head of Commercial Policy at Geistlich and a health economist working at the intersection of commercial pricing and global health. He spent fifteen years in pricing, market access and commercial strategy, including five years as Strategic Pricing Director at Sonova, where he led global pricing across more than thirty countries and built its global pricing governance. His health economics research at the Swiss TPH focuses on equitable access to health technologies and interventions in lower-income countries, and he has contributed to World Health Organization (WHO) guidance on malaria strategy. He is completing an MBA in International Health Management at the University of Basel and has spoken at previous editions of the Forum in Berlin and Montreux.

Silvia Antonelli is Senior Director, Pricing, Reimbursement & Access at Eli Lilly Italia, where she leads the PRA team across the company’s portfolio. She joined Lilly in 2013 and has built her career in market access, with extensive experience in AIFA price and reimbursement negotiations, managed entry agreements, payback mechanisms and regional access. She has led pricing and access strategy for launches across diabetes, obesity, neuroscience, immunology and oncology.

Ruven is a Principal and Chief Commercial Officer at Marbls based out of Switzerland and has worked more than 19 years in Life Sciences in European and International markets with a primary focus in Pricing, Contracting, Tendering and Commercial Excellence. Ruven began his early career working in industry for Top 5 pharmaceutical manufacturers in tendering, contracting, and commercial effectiveness, from local to global roles. After which, Ruven joined HighPoint Solutions where he started and led consulting services in Europe for Global Pricing, Contracting and Tender Management. Ruven was responsible for developing teams, creating solutions, business development and project oversight as well as delivering services across clients from pharma, medical device to biosimilar & generic manufacturers. In addition, he was responsible for managing the international partnerships and Thought Leadership initiatives. Throughout the acquisition by IQVIA, Ruven became in charge of the legacy European HighPoint team. Ruven’s focus continues in Global Pricing, Contracting & Tender Management and Commercial Excellence, as well as the Commercial Strategy of Marbls.